Q-omics provides the consensus-scored PNMA5 profile across patient tissues and cancer cell-line models. PNMA5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PNMA5 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, PNMA5 RNA expression shows 11,147 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, and THYM as cancer lineages where PNMA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNMA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNMA5 survival associations across molecular data types. PNMA5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNMA5 RNA expression–survival associations across cancer types. High PNMA5 expression shows unfavorable associations in KICH and COAD, but favorable associations in HNSC, LUAD, OV and ESCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KICH as the clearest survival context for PNMA5 RNA expression.
This table summarizes PNMA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for PNMA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNMA5 shows lower tumor expression in KICH, KIRP and BRCA and higher tumor expression in COAD, STAD and LUSC. The KICH box plot shows higher PNMA5 RNA expression in normal versus tumor tissue (log2 FC = −0.041, t-test p = .001).
This table shows molecular features associated with PNMA5 in patient tissues and cancer cell lines. In patient samples, PNMA5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PNMA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
